Domain Therapeutics Secures €3.5M Funding to Advance Small Molecule GPCR-Targeted Therapies for Cancer and Other Cellular Diseases

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on May 28, local time in France, biopharmaceutical company Domain Therapeutics completed a €3.5 million financing round. The proceeds from this round will be used to support the company’s next phase of clinical drug research and to expand its business operations.

It is reported that this round of financing was participated in by existing shareholders of Domain Therapeutics.

Domain Therapeutics, founded in 2001 and headquartered in Alsace, France, is a biopharmaceutical company focused on the development of small-molecule drugs targeting G protein-coupled receptors (GPCRs) for the treatment of central nervous system disorders, cancer, and immune system impairments.

Under the leadership of CEO Pascal Neuville, Domain Therapeutics currently focuses its business on three main areas: collaborating with multiple pharmaceutical companies to develop new drugs, innovating the performance of BioSens-All™ series products, and developing an internal pipeline for clinical disease treatment.

The company’s biological products primarily target G protein-coupled receptors (GPCRs) to facilitate disease treatment in the human body. These GPCR-targeting drugs offer three key advantages: (1) Identification of allosteric modulators with superior efficacy. Through biological analysis of human GPCRs, researchers can selectively screen for allosteric modulators better suited to individual patients, enabling efficient treatment of affected tissues; (2) Selection of biased ligands with enhanced safety profiles. The company’s drugs allow for pre-modulation of diseased tissues, enabling medical teams to choose more appropriate biased ligands for treatment after observing changes in human tissue responses; (3) Addressing orphan diseases and other challenging conditions that remain difficult to treat globally. GPCR-related disorders have long been a major challenge in the medical community, and the therapeutic agents developed by this company provide a solution to this persistent problem.

DTect-All™ is one of the company’s flagship products, a biological platform developed by Professor Marcel Hibert, Dr. Jean-Luc Galzi, and their team at the University of Strasbourg. This platform enables the coupling of GPCRs with their cognate ligands within an integrated system. Selection on this platform is based solely on binding affinity, irrespective of the biological activity of the selected ligands.

During the matching process on the DTect-All™ platform, researchers must first integrate fluorescently labeled proteins onto GPCRs to enable real-time tracking of GPCR dynamics by the detector. When a GPCR binds to a specific ligand, the fluorescent proteins on its surface disperse onto the ligand’s surface. Based on the distinct properties of different fluorescent proteins, researchers can identify the target ligands that match the GPCR and proceed with subsequent studies.

Pascal Neuville, CEO of Domain Therapeutics, stated, “We are deeply grateful to our shareholders for their strong support. The company is currently in a golden period of development. We plan to leverage the funds from this new round of financing to further expand our business operations and market presence, innovate our corporate development model and product portfolio, and create greater value for our shareholders. The global healthcare market places significant emphasis on GPCR-targeted therapies, and we aspire to become an industry leader, helping patients worldwide regain their health as soon as possible.”

(Compiled by Liu Yujing)